Portfolio Holdings Detail for ISIN IE000NITTFF2
| Stock Name / Fund | iShares Russell 1000 Growth UCITS ETF |
| Issuer | Blackrock |
| Entity holding fund | iShares VII Public Limited Company |
| Entity Type | Umbrella investment company with variable capital and having segregated liability between its funds |
| Entity LEI | 549300Q7FFITMZ2PFZ28 |
| ETF Ticker | R1GR(USD) AS |
| ETF Ticker | R1GR(USD) Euronext Amsterdam |
Holdings detail for SRPT
| Stock Name | Sarepta Therapeutics Inc |
| Ticker | SRPT(USD) NASDAQ |
| TYPE | Common Stock |
| Country | USA |
| ISIN | US8036071004 |
| LEI | 549300IKDPIED8J8IG21 |
Show aggregate SRPT holdings
News associated with SRPT
- Leerink Partners Boosts Sarepta Therapeutics (NASDAQ:SRPT) Price Target to $15.00
- Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) had its price target raised by analysts at Leerink Partners from $12.00 to $15.00 in a report issued on Tuesday,Benzinga reports. The firm currently has a “market perform” rating on the biotechnology company’s stock. Leerink Partners’ price target would indicate a potential downside of 12.89% from the stock’s […] - 2025-09-11 03:04:49
- After Hours Most Active for Aug 29, 2025 : ELAN, NVDA, GOOG, PPBI, SRPT, COLB, MSFT, SNAP, KMI, XOM, NEE, PFE
- The NASDAQ 100 After Hours Indicator is down -7.17 to 23,408.25. The total After hours volume is currently 173,977,891 shares traded.The following are the most active stocks for the after hours session: Elanco Animal Health Incorporated (ELAN) is unchanged at $18.35, with 22,912 - 2025-08-29 17:29:12
- HC Wainwright Reiterates “Sell” Rating for Sarepta Therapeutics (NASDAQ:SRPT)
- Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “sell” rating reiterated by equities research analysts at HC Wainwright in a report released on Monday,Benzinga reports. A number of other research firms have also issued reports on SRPT. Barclays raised shares of Sarepta Therapeutics from an “underweight” rating to an “equal weight” rating and […] - 2025-08-27 02:30:45
- SCHK's Underlying Holdings Could Mean 11% Gain Potential
- Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-08-21 10:39:22
- Sarepta Therapeutics (NASDAQ:SRPT) Given New $17.00 Price Target at Bank of America
- Sarepta Therapeutics (NASDAQ:SRPT – Free Report) had its price objective lifted by Bank of America to $17.00 in a research note issued to investors on Wednesday,Benzinga reports. They currently have an underperform rating on the biotechnology company’s stock. Other equities analysts have also issued reports about the company. Baird R W lowered Sarepta Therapeutics from […] - 2025-08-21 04:58:48
- Sarepta Therapeutics (NASDAQ:SRPT) Price Target Raised to $12.00
- Sarepta Therapeutics (NASDAQ:SRPT – Free Report) had its price objective hoisted by Deutsche Bank Aktiengesellschaft to $12.00 in a research note released on Friday,Benzinga reports. Deutsche Bank Aktiengesellschaft currently has a sell rating on the biotechnology company’s stock. Other research analysts have also issued reports about the stock. TD Cowen lowered shares of Sarepta Therapeutics […] - 2025-08-18 03:06:45
- Vanguard Group Inc. Decreases Stake in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)
- Vanguard Group Inc. lowered its position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Free Report) by 0.6% in the 1st quarter, according to the company in its most recent filing with the SEC. The fund owned 9,032,613 shares of the biotechnology company’s stock after selling 52,843 shares during the quarter. Vanguard Group Inc. owned about 0.09% […] - 2025-08-14 04:37:10
- Stocks Rally on Positive Tariff News ad Rate Cut Hopes
- The S&P 500 Index ($SPX ) (SPY ) today is up +0.48%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.39%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.71%. September E-mini S&P futures (ESU25 ) are up +0.53%, and September E-mini Nasdaq futures... - 2025-08-07 18:57:35
- Stocks Rally on Positive Tariff News ad Rate Cut Hopes
- The S&P 500 Index ($SPX ) (SPY ) today is up +0.48%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.39%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.71%. September E-mini S&P futures (ESU25 ) are up +0.53%, and September E-mini Nasdaq futures... - 2025-08-07 13:11:34
- Stocks Rally on Positive Tariff News ad Rate Cut Hopes
- The S&P 500 Index ($SPX ) (SPY ) today is up +0.48%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.39%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.71%. September E-mini S&P futures (ESU25 ) are up +0.53%, and September E-mini Nasdaq futures... - 2025-08-07 12:48:17
- Stocks Rally on Positive Tariff News ad Rate Cut Hopes
- The S&P 500 Index ($SPX ) (SPY ) today is up +0.48%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +0.39%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.71%. September E-mini S&P futures (ESU25 ) are up +0.53%, and September E-mini Nasdaq futures... - 2025-08-07 12:41:53
- Barclays Upgrades Sarepta Therapeutics (NASDAQ:SRPT) to “Equal Weight”
- Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) was upgraded by analysts at Barclays from an “underweight” rating to an “equal weight” rating in a research report issued to clients and investors on Tuesday, MarketBeat.com reports. The firm currently has a $22.00 target price on the biotechnology company’s stock. Barclays‘s price objective indicates a potential upside […] - 2025-07-31 05:26:59
- Sarepta Therapeutics (NASDAQ:SRPT) Stock Rating Upgraded by Barclays
- Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) was upgraded by research analysts at Barclays from an “underweight” rating to an “equal weight” rating in a report released on Tuesday, MarketBeat Ratings reports. The brokerage presently has a $22.00 target price on the biotechnology company’s stock. Barclays‘s price target would indicate a potential upside of 35.38% […] - 2025-07-31 05:26:59
- Sarepta Therapeutics (NASDAQ:SRPT) Upgraded to Equal Weight at Barclays
- Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) was upgraded by stock analysts at Barclays from an “underweight” rating to an “equal weight” rating in a research note issued on Tuesday, Marketbeat reports. The brokerage presently has a $22.00 price target on the biotechnology company’s stock. Barclays‘s price objective points to a potential upside of 31.34% […] - 2025-07-31 05:26:59
- BMO Capital Markets Forecasts Strong Price Appreciation for Sarepta Therapeutics (NASDAQ:SRPT) Stock
- Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) had its price target hoisted by BMO Capital Markets from $25.00 to $50.00 in a report issued on Tuesday,Benzinga reports. The brokerage currently has a “market perform” rating on the biotechnology company’s stock. BMO Capital Markets’ price objective would indicate a potential upside of 198.51% from the stock’s […] - 2025-07-31 05:26:58
- William Blair Reaffirms “Outperform” Rating for Sarepta Therapeutics (NASDAQ:SRPT)
- Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “outperform” rating reissued by investment analysts at William Blair in a research report issued on Tuesday,RTT News reports. Other equities analysts have also recently issued reports about the stock. Bank of America reaffirmed an “underperform” rating on shares of Sarepta Therapeutics in a report on […] - 2025-07-31 05:26:58
- Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Expected to Rise, Morgan Stanley Analyst Says
- Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) had its price objective hoisted by equities researchers at Morgan Stanley from $15.00 to $20.00 in a report released on Tuesday,Benzinga reports. The brokerage currently has an “equal weight” rating on the biotechnology company’s stock. Morgan Stanley’s price target suggests a potential upside of 19.40% from the stock’s […] - 2025-07-31 03:02:52
- HC Wainwright Reaffirms Sell Rating for Sarepta Therapeutics (NASDAQ:SRPT)
- Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “sell” rating restated by analysts at HC Wainwright in a note issued to investors on Tuesday, MarketBeat.com reports. A number of other equities research analysts also recently commented on SRPT. Piper Sandler reduced their price objective on shares of Sarepta Therapeutics from $32.00 to $18.00 […] - 2025-07-31 03:02:51
- Sarepta Therapeutics (NASDAQ:SRPT) Stock Rating Upgraded by JPMorgan Chase & Co.
- Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) was upgraded by equities researchers at JPMorgan Chase & Co. from an “underweight” rating to a “neutral” rating in a research note issued to investors on Tuesday, Marketbeat.com reports. The brokerage currently has a $24.00 target price on the biotechnology company’s stock. JPMorgan Chase & Co.‘s price target […] - 2025-07-31 03:02:51
- Stocks Retreat Ahead of Results from Wednesday's FOMC Meeting
- The S&P 500 Index ($SPX ) (SPY ) Tuesday closed down -0.30%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.46%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.21%. September E-mini S&P futures (ESU25 ) fell -0.30%, and September E-mini Nasdaq futures (NQU25... - 2025-07-30 12:49:47
- Stocks Retreat Ahead of Results from Wednesday's FOMC Meeting
- The S&P 500 Index ($SPX ) (SPY ) Tuesday closed down -0.30%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.46%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.21%. September E-mini S&P futures (ESU25 ) fell -0.30%, and September E-mini Nasdaq futures (NQU25... - 2025-07-30 08:23:02
- Sarepta Therapeutics (NASDAQ:SRPT) Earns “Underperform” Rating from Needham & Company LLC
- Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “underperform” rating reaffirmed by Needham & Company LLC in a report issued on Monday,Benzinga reports. Several other equities analysts have also recently issued reports on SRPT. Scotiabank raised Sarepta Therapeutics from a “sector perform” rating to a “sector outperform” rating and set a $80.00 price […] - 2025-07-30 04:54:53
- Barclays Downgrades Sarepta Therapeutics (NASDAQ:SRPT) to Strong Sell
- Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report) was downgraded by equities research analysts at Barclays from a “hold” rating to a “strong sell” rating in a report released on Monday, MarketBeat Ratings reports. Other research analysts have also recently issued research reports about the stock. HC Wainwright reaffirmed a “sell” rating on shares of Sarepta […] - 2025-07-30 04:54:51
- Stocks Retreat Ahead of Results from Wednesday's FOMC Meeting
- The S&P 500 Index ($SPX ) (SPY ) Tuesday closed down -0.30%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.46%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed down -0.21%. September E-mini S&P futures (ESU25 ) fell -0.30%, and September E-mini Nasdaq futures (NQU25... - 2025-07-30 03:41:41
- Sarepta Therapeutics (NASDAQ:SRPT) Shares Gap Up Following Analyst Upgrade
- Sarepta Therapeutics, Inc. (NASDAQ:SRPT – Get Free Report) shares gapped up before the market opened on Tuesday after Barclays upgraded the stock from an underweight rating to an equal weight rating. The stock had previously closed at $13.86, but opened at $18.23. Barclays now has a $22.00 price target on the stock. Sarepta Therapeutics shares […] - 2025-07-30 02:14:47
- Strong Earnings and Trade Deal Optimism Bolster Stocks
- The S&P 500 Index ($SPX ) (SPY ) today is up +0.21%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.02%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.56%. September E-mini S&P futures (ESU25 ) are up +0.15%, and September E-mini Nasdaq futures... - 2025-07-29 20:49:20
- Stocks Slide in Afternoon Session
- The S&P 500 Index ($SPX ) (SPY ) today is down -0.27%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.48%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -0.25%. After starting off the day stronger, the 3 major stock indxes are in the... - 2025-07-29 20:19:00
- Stocks Supported by Strong Earnings and Trade Deal Optimism
- The S&P 500 Index ($SPX ) (SPY ) today is up +0.05%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.25%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.25%. September E-mini S&P futures (ESU25 ) are up +0.03%, and September E-mini Nasdaq futures... - 2025-07-29 14:38:53
- Stocks Supported by Strong Earnings and Trade Deal Optimism
- The S&P 500 Index ($SPX ) (SPY ) today is up +0.05%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.25%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.25%. September E-mini S&P futures (ESU25 ) are up +0.03%, and September E-mini Nasdaq futures... - 2025-07-29 14:12:43
- Strong Earnings and Trade Deal Optimism Bolster Stocks
- The S&P 500 Index ($SPX ) (SPY ) today is up +0.21%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.02%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.56%. September E-mini S&P futures (ESU25 ) are up +0.15%, and September E-mini Nasdaq futures... - 2025-07-29 14:12:42
iShares Russell 1000 Growth UCITS ETF SRPT holdings
| Date | Number of SRPT Shares Held | Base Market Value of SRPT Shares | Local Market Value of SRPT Shares | Change in SRPT Shares Held | Change in SRPT Base Value | Current Price per SRPT Share Held | Previous Price per SRPT Share Held |
|---|
| 2025-12-03 (Wednesday) | 1,356 | USD 29,615 | USD 29,615 | 13 | USD 2,124 | USD 21.84 | USD 20.4698 |
| 2025-12-02 (Tuesday) | 1,343 | USD 27,491 | USD 27,491 | 0 | USD 1,007 | USD 20.4698 | USD 19.72 |
| 2025-12-01 (Monday) | 1,343 | USD 26,484 | USD 26,484 | 0 | USD -2,176 | USD 19.72 | USD 21.3403 |
| 2025-11-28 (Friday) | 1,343 | USD 28,660 | USD 28,660 | 0 | USD 524 | USD 21.3403 | USD 20.9501 |
| 2025-11-27 (Thursday) | 1,343 | USD 28,136 | USD 28,136 | 0 | USD 0 | USD 20.9501 | USD 20.9501 |
| 2025-11-26 (Wednesday) | 1,343 | USD 28,136 | USD 28,136 | 0 | USD 2,149 | USD 20.9501 | USD 19.35 |
| 2025-11-25 (Tuesday) | 1,343 | USD 25,987 | USD 25,987 | 0 | USD 591 | USD 19.35 | USD 18.9099 |
| 2025-11-24 (Monday) | 1,343 | USD 25,396 | USD 25,396 | 0 | USD 1,638 | USD 18.9099 | USD 17.6902 |
| 2025-11-21 (Friday) | 1,343 | USD 23,758 | USD 23,758 | 13 | USD 1,840 | USD 17.6902 | USD 16.4797 |
| 2025-11-20 (Thursday) | 1,330 | USD 21,918 | USD 21,918 | 0 | USD 119 | USD 16.4797 | USD 16.3902 |
| 2025-11-19 (Wednesday) | 1,330 | USD 21,799 | USD 21,799 | 0 | USD -1,396 | USD 16.3902 | USD 17.4398 |
| 2025-11-18 (Tuesday) | 1,330 | USD 23,195 | USD 23,195 | 0 | USD -133 | USD 17.4398 | USD 17.5399 |
| 2025-11-17 (Monday) | 1,330 | USD 23,328 | USD 23,328 | 0 | USD -1,689 | USD 17.5399 | USD 18.8098 |
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdingsShare Trades of SRPT by Blackrock for IE000NITTFF2
Show aggregate share trades of SRPT| Date | Action | Quantity | Market High | Market Low | Likely Trade Price | Likely Trade Value (Profit/Loss) | Average Price previous trades |
|---|
| 2025-12-03 | BUY | 13 | | | 21.840* | | 60.76 |
| 2025-11-21 | BUY | 13 | | | 17.690* | | 62.36 |
| 2025-11-03 | BUY | 13 | 24.550 | 22.670 | 22.858 | USD 297 | 65.62 |
| 2025-10-30 | BUY | 13 | 23.390 | 22.788 | 22.848 | USD 297 | 66.07 |
| 2025-09-30 | BUY | 13 | 19.270 | 19.340 | 19.333 | USD 251 | 70.14 |
| 2025-09-24 | SELL | -13 | 18.260 | 18.460 | 18.440 | USD -240 | 71.37 Profit of 688 on sale |
| 2025-08-20 | BUY | 13 | 20.580 | 20.660 | 20.652 | USD 268 | 75.09 |
| 2025-08-18 | BUY | 39 | 20.990 | 22.050 | 21.944 | USD 856 | 75.79 |
| 2025-07-21 | BUY | 13 | 13.320 | 13.950 | 13.887 | USD 181 | 76.20 |
| 2025-07-09 | SELL | -26 | 19.370 | 19.740 | 19.703 | USD -512 | 78.54 Profit of 1,530 on sale |
| 2025-07-08 | BUY | 26 | 19.030 | 19.360 | 19.327 | USD 503 | 78.94 |
| 2025-07-02 | BUY | 52 | 18.200 | 18.350 | 18.335 | USD 953 | 80.65 |
| 2025-06-04 | BUY | 48 | 39.540 | 40.280 | 40.206 | USD 1,930 | 88.22 |
| 2025-05-21 | BUY | 96 | 40.050 | 44.140 | 43.731 | USD 4,198 | 92.56 |
| 2025-05-01 | BUY | 11 | 62.780 | 64.000 | 63.878 | USD 703 | 99.40 |
| 2025-04-22 | BUY | 33 | 59.310 | 59.330 | 59.328 | USD 1,958 | 102.28 |
| 2025-04-16 | BUY | 132 | 53.940 | 55.010 | 54.903 | USD 7,247 | 104.41 |
| 2025-04-14 | BUY | 11 | 54.630 | 54.640 | 54.639 | USD 601 | 105.55 |
| 2025-04-10 | BUY | 11 | 50.310 | 54.470 | 54.054 | USD 595 | 106.82 |
| 2025-04-07 | SELL | -33 | 52.400 | 55.170 | 54.893 | USD -1,811 | 108.79 Profit of 1,779 on sale |
| 2025-03-31 | BUY | 11 | 63.820 | 67.470 | 67.105 | USD 738 | 111.23 |
| 2025-03-27 | BUY | 55 | 71.810 | 73.950 | 73.736 | USD 4,055 | 112.27 |
| 2025-03-19 | BUY | 11 | 79.970 | 80.980 | 80.879 | USD 890 | 115.41 |
| 2025-03-18 | BUY | 11 | 73.540 | 81.870 | 81.037 | USD 891 | 116.01 |
| 2025-02-27 | BUY | 11 | 103.060 | 109.500 | 108.856 | USD 1,197 | 118.95 |
| 2025-02-25 | SELL | -11 | 106.950 | 107.110 | 107.094 | USD -1,178 | 119.38 Profit of 135 on sale |
| 2025-02-24 | SELL | -11 | 105.560 | 107.540 | 107.342 | USD -1,181 | 119.63 Profit of 135 on sale |
| 2025-02-06 | BUY | 11 | 112.110 | 119.270 | 118.554 | USD 1,304 | 122.58 |
| 2025-02-05 | BUY | 11 | 119.020 | 120.050 | 119.947 | USD 1,319 | 122.67 |
| 2024-12-10 | BUY | 11 | 126.700 | 129.370 | 129.103 | USD 1,420 | 124.50 |
| 2024-12-09 | BUY | 11 | 129.000 | 131.310 | 131.079 | USD 1,442 | 124.35 |
| 2024-12-02 | SELL | -11 | 127.950 | 132.650 | 132.180 | USD -1,454 | 123.84 Loss of -92 on sale |
| 2024-11-25 | BUY | 11 | 114.650 | 115.300 | 115.235 | USD 1,268 | 122.17 |
| 2024-11-08 | BUY | 33 | 121.610 | 121.960 | 121.925 | USD 4,024 | 127.34 |
| 2024-11-06 | BUY | 11 | 127.970 | 128.320 | 128.285 | USD 1,411 | 127.87 |
| 2024-10-30 | BUY | 11 | 127.780 | 130.850 | 130.543 | USD 1,436 | 129.89 |
| 2024-10-22 | SELL | -216 | 128.420 | 128.540 | 128.528 | USD -27,762 | 127.31 Loss of -263 on sale |
Market high and low price is on the date. * (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection
The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close
Shorting History of SRPT
| Date | Shorted Volume | Short Exempt Volume | Total Shares Traded | % Shorted |
|---|
| 2025-09-19 | 983,569 | 11,582 | 2,229,356 | 44.1% |
| 2025-09-18 | 1,090,475 | 13,256 | 2,892,181 | 37.7% |
| 2025-09-17 | 1,084,432 | 12,646 | 2,880,085 | 37.7% |
| 2025-09-16 | 894,021 | 24,794 | 2,572,516 | 34.8% |
| 2025-09-15 | 965,390 | 17,413 | 1,966,976 | 49.1% |
| 2025-09-12 | 653,958 | 4,450 | 1,496,524 | 43.7% |
| 2025-09-11 | 1,072,912 | 20,779 | 2,821,710 | 38.0% |
| 2025-09-10 | 1,151,235 | 26,938 | 2,519,731 | 45.7% |
| 2025-09-09 | 912,384 | 5,700 | 1,971,308 | 46.3% |
| 2025-09-08 | 1,691,086 | 14,236 | 3,124,457 | 54.1% |
| 2025-09-05 | 983,688 | 32,929 | 2,352,178 | 41.8% |
| 2025-09-04 | 914,125 | 4,094 | 1,995,501 | 45.8% |
| 2025-09-03 | 1,510,137 | 28,081 | 3,442,477 | 43.9% |
| 2025-09-02 | 1,295,420 | 1,742 | 2,645,873 | 49.0% |
| 2025-08-29 | 1,216,368 | 8,598 | 2,467,992 | 49.3% |
| 2025-08-28 | 1,059,025 | 4,645 | 2,463,626 | 43.0% |
| 2025-08-27 | 1,514,636 | 213 | 2,902,512 | 52.2% |
| 2025-08-26 | 1,565,998 | 49,895 | 3,527,435 | 44.4% |
| 2025-08-25 | 2,838,958 | 5,229 | 6,270,840 | 45.3% |
| 2025-08-22 | 1,981,782 | 31,841 | 4,688,703 | 42.3% |
| 2025-08-21 | 4,086,130 | 90,917 | 7,046,331 | 58.0% |
| 2025-08-20 | 1,278,705 | 4,510 | 2,928,741 | 43.7% |
| 2025-08-19 | 876,314 | 1,494 | 2,229,424 | 39.3% |
| 2025-08-18 | 1,204,430 | 3,010 | 2,779,040 | 43.3% |
| 2025-08-15 | 1,705,867 | 9,186 | 4,100,040 | 41.6% |
| 2025-08-14 | 1,349,441 | 835 | 3,381,579 | 39.9% |
| 2025-08-13 | 1,545,265 | 20,760 | 5,282,331 | 29.3% |
| 2025-08-12 | 1,305,838 | 2,507 | 3,231,125 | 40.4% |
| 2025-08-11 | 2,168,673 | 9,152 | 5,077,985 | 42.7% |
| 2025-08-08 | 2,133,503 | 14,932 | 4,694,284 | 45.4% |
| 2025-08-07 | 3,771,974 | 42,479 | 7,573,979 | 49.8% |
| 2025-08-06 | 2,783,503 | 4,476 | 5,375,055 | 51.8% |
| 2025-08-05 | 1,594,846 | 676 | 3,432,445 | 46.5% |
| 2025-08-04 | 4,127,057 | 3,778 | 7,480,149 | 55.2% |
| 2025-08-01 | 2,097,751 | 4,035 | 4,221,318 | 49.7% |
| 2025-07-31 | 3,263,532 | 32,143 | 7,100,489 | 46.0% |
| 2025-07-30 | 8,885,536 | 12,372 | 18,507,337 | 48.0% |
| 2025-07-29 | 17,694,154 | 67,608 | 30,461,995 | 58.1% |
| 2025-07-28 | 4,761,652 | 590,396 | 9,578,710 | 49.7% |
| 2025-07-25 | 2,445,819 | 120,878 | 5,876,922 | 41.6% |
| 2025-07-24 | 9,985,202 | 652,750 | 20,571,463 | 48.5% |
| 2025-07-23 | 1,525,839 | 5,307 | 4,030,266 | 37.9% |
| 2025-07-22 | 4,478,481 | 383,133 | 10,024,476 | 44.7% |
| 2025-07-21 | 3,426,188 | 78,320 | 9,225,506 | 37.1% |
| 2025-07-18 | 11,983,277 | 545,936 | 29,286,071 | 40.9% |
The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.
Back to Listing
Note: All information is provided as is without warranty and should be used for indicative purposes only.
You should independently check data before making any investment decision.
This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability.
Copyright Market Footprint Ltd. Privacy Policy